METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE
AssigneeAdvanced Immune Therapeutics, Inc.
InventorsBirgit C. Schultes, Christopher F. Nicodemus
Life of this patent
Estimating the term…
Abstract
The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.
Claims24
A method for increasing the bioactivity of a therapeutic IgE antibody in a patient comprising administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent selected from the group consisting of:
- immunostimulatory compounds;
- chemotherapeutic agents;
- immunosuppressive agents;
- and any combination thereof, in an amount effective to increase the bioactivity of the therapeutic IgE antibody as compared to the administration of the therapeutic IgE antibody alone.
A method for increasing the bioactivity of a therapeutic IgE antibody toward a tumor in a patient comprising administering to the patient a therapeutic IgE antibody specific for an antigen associated with the tumor in combination with at least one bioactivity-enhancing agent selected from the group consisting of:
- immunostimulatory compounds, chemotherapeutic agents, immunosuppressive agents, and any combination thereof, in an amount effective to increase the bioactivity of the therapeutic IgE antibody as compared to the administration of the therapeutic IgE antibody alone.
A method of increasing the biosafety of a therapeutic IgE monoclonal antibody in a patient comprising administering a therapeutic IgE monoclonal antibody wherein the IgE antibody comprises a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive optionally in combination with a bioactivity enhancing agent in an amount effective to increase the biosafety of the IgE monoclonal antibody as compared to the biosafety of the IgE antibody when administered alone.
A method of increasing the bioactivity of a therapeutic IgE antibody comprising the step of administering an IgE antibody to a patient in an amount effective to induce direct IgE antibody mediated toxicity against the antigen and diseased cells and induce antigen processing and cross presentation to induce Tc1 T-cell mediated cellular immune response to the antigen in a patient capable of mounting such responses.
Dependencies are inferred from the claim text.